Elazer R. Edelman, M.D., Ph.D., F.A.C.C.

AIMBE College of Fellows Class of 2001
For embodying the melding of science and medicine, engineering and biology; leveraging technical innovation with rigorous thought to unravel mechanisms of disease.

CBSET: Preclinical Safety Studies Must Include Equally Balanced Male/Female Animal Models to Shed Light on Sex-Dependent Vascular Responses in Humans

Via Business Wire | February 12, 2018

CBSET, a non-for-profit preclinical research institute dedicated to biomedical research, education and advancement of medical technologies, announced today that its scientists have published data and analyses (“Sex differences in the outcomes of stent implantation in mini-swine model”) that “illustrate differences in the dynamic healing responses of male and female pigs to stent implantation in single and overlapped configurations.” The study is published online by the multidisciplinary and Open Source journal PLOS ONE.

“Animals are ideal models for testing specific hypotheses that drive vascular disease. In fact, much of what we know of vascular biology is derived from animal work. Over the years we have used male and female animals to evaluate a large range of endovascular stents yet, in retrospect, none of these individual studies was sufficiently powered to capture sex-dependent effects,” said Peter Markham, MS, President and CEO of CBSET and co-senior author of the article. “It is only when we pooled years of data that we were able to find sex-related differences in vascular responses to stent implantation.”

“The accentuation of sex-dependent differences in vascular responses at six months and one year are intriguing given the consideration of erodible scaffolds, and even non-implantable endovascular therapies such as drug-coated balloons. Time will tell if our findings in juvenile pigs extend to the clinical setting, yet already they provide context for preclinical safety studies and illustrate how more-refined animal models might shed light on sex dependent vascular responses in humans,” said Elazer Edelman, MD, PhD, chairman and co-founder of CBSET, and co-senior author of the paper… Continue reading.


Elazer Edelman honored with Cardiovascular Research Foundation career achievement award

Via MIT | October 13, 2017

Elazer Edelman, the Thomas D. and Virginia W. Cabot Professor of Health Sciences at MIT, has been awarded this year’s Transcatheter Cardiovascular Therapeutics (TCT) Career Achievement Award ­for his extraordinary contributions to the field of cardiology.

A lifelong researcher and innovator, Edelman is core member of the Institute for Medical Engineering and Science, director of the Harvard-MIT Biomedical Engineering Center, a professor of medicine at Harvard Medical School, and a senior attending physician at Brigham and Women’s Hospital. He and his students have been credited as some of the key contributors and pioneers of the coronary stent.

His research examining the cellular and molecular mechanisms that produce atherosclerosis and coronary artery disease critically advanced the development and optimization of the first bare-metal stents and subsequent iterations, including drug-eluting stents. His most recent publications have focused on how tissue engineered cells might be used for the local delivery of growth factors and growth inhibitors in the study of the vascular homeostasis and repair, cancer invasiveness and metastases, and the homology between endothelial paracrine and angiocrine regulation in cancer and vascular diseases… Continue reading.


Metastasis Study Illuminates How Cancer Will ‘Hijack’ Healthy Cells

Via Harvard | December 16, 2015

Metastasis — the spread of cancer from one part of the body to others — accounts for more than 90 percent of cancer-related deaths. Although the cells that seed metastasis and the sites they tend to travel to have been increasingly studied over the years, little has been known about how cancer migrates from a primary site, such as breast tissue, to a secondary site, such as the brain or bone marrow.

A study by researchers from Harvard-affiliated Brigham and Women’s Hospital (BWH), published in Nature Communications, offers a new view of how cancer cells extend their reach, co-opting and transforming normal cells through “metastatic hijacking.” The researchers also find that in preclinical models, pharmacological intervention can stop the hijack before it starts, pointing to new therapeutic targets for preventing cancer cells from spreading.

“Metastasis remains a final frontier in the search for a cure for cancer,” said Shiladitya Sengupta of BWH’s Bioengineering Division in the Department of Medicine and corresponding author of the study. “For the past five years we have studied how cancer travels to other parts of the body, and what we find is that communication is key.”

“By working together, our labs have been able to gain greater insights into cell-cell communication in tumor states, which will shed new light on cancer as a disease and the promise and potential of emerging innovative therapies,” said Elazer Edelman of BWH’s Cardiovascular Division in the Department of Medicine.


Health Sciences, Technology Expert Edelman Set for Discovery Lecture

Via Vanderbilt | October 29, 2015

Elazer Edelman, M.D., Ph.D., a pioneer in the application of engineering and physical sciences to understand fundamental biological processes and the mechanisms of disease, will deliver the next Flexner Discovery Lecture on Thursday, Nov. 5.

Edelman is the Thomas D. and Virginia W. Cabot Professor of Health Sciences and Technology at the Massachusetts Institute of Technology (MIT), professor of Medicine at Harvard Medical School, director of the Harvard-MIT Biomedical Engineering Center and a member of the Institute of Medicine and National Academy of Engineering.